Trial Profile

A Single-arm, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of HL-085 in Advanced Melanoma Patients With NRAS Mutation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tunlametinib (Primary)
Indications Malignant melanoma
Focus Registrational; Therapeutic Use
Sponsors Kechow Pharma

Most Recent Events

04 Jun 2024 Results reporting Overall survival and efficacy subgroup analysis of tunlametinib, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
18 Mar 2024 Results published in a KeChow Pharma Media Release
18 Mar 2024 According to a KeChow Pharma media release, China National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with NRAS mutated advanced melanoma who were previously treated with PD-1/PD-L1.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com